# US 2020/0345055 A1 · Activation of conditionally-expressed oligosaccharide pathways during fermentation of probiotic strains

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0345055 A1
- Document ID: US20200345055A1
- Status: Published application
- Kind: A1
- Application number: 16/962,627
- Filed: 2019-01-18
- Published: 2020-11-05
- Earliest claimed: 2018-01-17
- Assignees: Evolve Biosystems Inc
- Applicants: Evolve Biosystems, Inc.
- Inventors: Steven FRESE
- Web page: https://patentgrep.com/patent/US20200345055A1

## CPC

- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A23C 9/12: Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C 9/203: {containing bifidus-active substances, e.g. lactulose; containing oligosaccharides}
- A23D 9/007: characterised by ingredients other than fatty acid triglycerides
- A23K 10/18: of live microorganisms
- A23K 20/163: Sugars; Polysaccharides
- A23L 29/30: containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin (products from apiculture A23L21/20; artificial sweetening agents A23L27/30)
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- C12N 1/04: Preserving or maintaining viable microorganisms (immobilised microorganisms C12N11/00)
- C12N 1/20: Bacteria; Culture media therefor
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A23V 2400/169: Plantarum
- A23V 2400/41: Pediococcus
- A23V 2400/529: Infantis
- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K 35/745: Bifidobacteria
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A23C: DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF (preservation thereof A23B11/00)
- A23D: EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS (preservation thereof A23B20/00; production, refinement or preservation of animal or vegetable fats or oils C11B, C11C)
- A23K: FODDER
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention relates generally to methods and compositions to achieve and maintain a desirable in vivo phenotype during fermentation and processing of food products for human or animal consumption. The methods and compositions of this invention require an activator that acts as a metabolic trigger for Mammalian Milk Oligosaccharide (MMO) consumption phenotype without necessarily requiring oligosaccharides (i.e a sugar polymer of 3 or more monosaccharides) within the fermentation medium. Compositions containing a non-oligosaccharide activator (e.g. monomers and dimers, and combinations thereof) may be used in fermentation processes of this invention. Turning on MMO-related genes without the use of oligosaccharides is one method of preparing activated commensal bacteria. Embodiments of this invention relate to a composition and a method for preparing a stable, activated and dormant form of commensal bacteria such as: bifidobacteria, lactobacilli or pediococci; for consumption by animals or humans, who are nursing or otherwise receiving MMOs as part of their diet.

## Claims

### Claim 1

A method of preparing activated commensal bacteria, said method comprising culturing said commensal bacterial sp. in the presence of an activator,
wherein said commensal bacteria are selected from the group consisting of Bifidobacterium, Lactobacillus, Pediococcus, Bacteroides, and Akkermansia,
wherein said activator is a carbohydrate monomer or dimer, and
wherein bacterial cells in the culture medium are activated by the presence of the activator included in the medium.

### Claim 2 (depends on 1)

The method of claim 1, wherein the activator is present at the initiation of the culture.

### Claim 3 (depends on 1)

The method of claim 1, wherein the activator is added after lag phase of the culture.

### Claim 4 (depends on 3)

The method of claim 3, wherein the activator is added no earlier than the middle of the exponential phase, but at least by the end of the exponential phase.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1 to 4 wherein activated commensal bacteria are recovered from the culture.

### Claim 6 (depends on 5)

The method of claim 5, wherein the recovered bacteria are spray-dried or freeze-dried.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A culture medium suitable for use in the method of any one of claims 1 to 6,
wherein said culture medium is adapted for culturing commensal bacteria,
wherein the fermentation ingredients of the culture medium are food grade and/or suitable for human or animal consumption, and
wherein said activator is a carbohydrate monomer or dimer.

### Claim 8 (depends on 7)

The culture medium of claim 7, wherein the culture medium is anaerobic and further wherein the culture medium comprises commensal bacteria selected from the group consisting of Bifidobacterium, Lactobacillus, Pediococcus, Bacteroides, and Akkermansia, which are activated.

### Claim 9 (depends on 7, 8)

The culture medium of claim 7 or claim 8, wherein the culture medium also comprises a non-activating carbon source.

### Claim 10 (depends on 9)

The culture medium of claim 9, wherein the activator constitutes 100%-1% of the total carbon source and non-activating carbohydrate constitutes 0%-99% of the total carbon source.

### Claim 11

A composition comprising an activator and activated commensal bacteria recovered from culture medium according to any one of the preceding claims.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the composition further comprises chitosan and/or chitin fragments, and/or mammalian milk oligosaccharides.

### Claim 13 (depends on 12)

The composition of claim 12 wherein the composition further comprises one or more of Lacto-N-biose, N-acetyllactosamine, Lacto-N-tetraose or Lacto-N-neo-tetraose

### Claim 14 (depends on 11, 12, 13)

The composition of any one of claims 11-13, wherein the composition is a powder with a water activity level of less than 0.35, less than 0.30, less than 0.25, less than 0.2, less than or less than 0.1.

### Claim 15 (depends on 11, 12, 13)

The composition of any one of claims 11-13, wherein the composition is an anhydrous composition.

### Claim 16 (depends on 11, 12, 13, 14, 15)

The composition of any one of claims 11-15, wherein the composition is in a powdered form.

### Claim 17 (depends on 11, 12, 13, 14, 15)

The composition of any one of claims 11-15, wherein the composition is in a dry form.

### Claim 18 (depends on 11, 12, 13, 14, 15, 16, 17)

The composition of any one of claims 11-17, wherein the composition is spray-dried or freeze-dried.

### Claim 19 (depends on 11, 12, 13, 14, 15, 16, 17, 18)

The composition of any one of claims 11-18, wherein the composition is dried in the presence of a suitable cryoprotectant.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the cryoprotectant is glucose, lactose, raffinose, sucrose, trehalose, adonitol, glycerol, mannitol, methanol, polyethylene glycol, propylene glycol, ribitol, alginate, bovine serum albumin, carnitine, citrate, cysteine, dextran, dimethyl sulphoxide, sodium glutamate, glycine betaine, glycogen, hypotaurine, peptone, polyvinyl pyrrolidone, or taurine, mammalian milk oligosaccharides, chitin, chitosan, other polysaccharides.

### Claim 21 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The composition of any one of claims 11-20, wherein the composition is suspended in an oil.

### Claim 22 (depends on 21)

The composition of claim 21, wherein the oil is a medium chain triglyceride.

### Claim 23 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The composition of any one of claims 11-20, wherein the composition is suspended in oligosaccharide syrup at GOS at least 57% where water activity is low enough to keep Bifidobacterium dormant.

### Claim 24 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The composition of any one of claims 11-23, wherein the composition is a food suitable to be fed to an animal or a human.

### Claim 25 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The composition of any one of claims 11-24 wherein the composition is formulated to be fed to a newborn animal, especially a newborn human.

### Claim 26

The method, the culture medium, or the composition of any one of the preceding claims, wherein said activator is selected from the compounds listed in Table 4,

### Claim 27

The method, the culture medium, or the composition of any one of the preceding claims, wherein the activator is selected from N-acetyl-glucosamine/galactosamine (NAG), dimeric N-acetyl-glucosamine, dimeric N-acetyl-galactosamine, fucose, sialic acid, lacto-N-biose, N-acetyl-lactosamine, galacto-N-bios, or Fuc-α-1,2-Gal-β.

### Claim 28 (depends on 26)

The method, the culture medium, or the composition of claim 26, wherein the activator is selected from N-acetyl-glucosamine/galactosamine (NAG), or dimeric N-acetyl-glucosamine.

### Claim 29 (depends on 26)

The method, the culture medium, or the composition of claim 26, wherein the activator is selected from Lacto-N biose or N-acetyl-lactosamine

### Claim 30

The method, the culture medium, or the composition of any one of the preceding claims, wherein once activated, commensal bacterial cells express a transport system capable of internalizing one or more oligosaccharides before said oligosaccharide is hydrolyzed and consequently said commensal bacterial cells are further capable of hydrolyzing said internalized oligosaccharide, wherein said oligosaccharide has the structure of an oligosaccharide found in a mammalian milk.

### Claim 31 (depends on 30)

The method of claim 30, wherein the mammalian milk is human, bovine, pig, rabbit, goat, sheep, camel, buffalo milk, or mixtures thereof.

### Claim 32

The method of any one of the preceding claims, wherein the activated commensal bacterial cells have a higher binding affinity to mammalian mucosal cells than commensal bacterial cells of the same species cultivated on non-activating monomers or dimers.

### Claim 33

The method, the culture medium, or the composition of any one of the preceding claims, wherein the activator is added in an amount from 0.1% to 10% of the culture medium (w/v), preferably from 0.1% to 3%.

### Claim 34

The method, the culture medium, or the composition of any one of the preceding claims, wherein the activator is present in an amount sufficient to induce expression of a gene encoding for a sialidase, a fucosidase, or an alpha-N-acetylgalactosaminidase, or genes listed in Table 1 or Table 2 in the bacterial cells.

### Claim 35

The method, the culture medium, or the composition of any one of the preceding claims, wherein activation of the commensal bacterial cells comprises upregulating Blon_0881 and Blon_2343 in B. infantis or the functional homologues in other bacterial species, said homologues being expressed during activation of said other bacterial species.

### Claim 36

The method, the culture medium, or the composition of any one of the preceding claims, wherein activation is glucosamine-6-phosphate isomerase and carbohydrate ABC transporter membrane protein from B. infantis or functional homologues from other Bifidobacterium, Lactobacillus and Pediococcus.

### Claim 37

The method, the culture medium, or the composition of any one of the preceding claims, wherein activation of the commensal bacterial cells comprises upregulating the genes selected from the group consisting of Blon_0042, Blon_R0015, Blon_R0017, Blon_R0021, Blon_R0022, Blon_2177 and combinations thereof, and/or downregulating genes selected from the group consisting of Blon_0518, Blon_0785, Blon_2167, Blon_2168 from B. infantis or the functional gene homologues from other Bifidobacterium, Lactobacillus and Pediococcus and combinations thereof.

### Claim 38

The method, the culture medium, or the composition of any one of the preceding claims, wherein the commensal bacterial cells comprise an upregulated Blon_0042 gene from B. infantis or the functional gene homologues from other Bifidobacterium, Lactobacillus, Pediococcus, Bacteroides, or Akkermansia.

### Claim 39

The method, the culture medium, or the composition of any one of the preceding claims, wherein the commensal bacterial cells comprise a downregulated Blon_2168 and/or Blon_2177 gene from B. infantis or the functional gene homologues from other Bifidobacterium, Lactobacillus and Pediococcus.

### Claim 40

The method, the culture medium, or the composition of any one of the preceding claims, wherein activation of the commensal bacterial cells comprise upregulating genes selected from the group consisting of Blon_0882, Blon_0881, Blon 0880, Blon_0879, Blon_2334, Blon_2335, Blon_2336, Blon_2337, Blon_2338, Blon_2339, Blon_2344, Blon_2346, Blon_2347, and Blon_2331 or their functional homologues in other species.

### Claim 41

The method, or the culture medium, or the composition of any one of the preceding claims, wherein the commensal bacteria are Bifidobacterium and the bacterium may be B. longum (subsp. longum, or infantis) B. B. breve, B. bifidum or B. pseudocatenulatum.

### Claim 42 (depends on 41)

The method, or the culture medium, or the composition of claim 41 wherein the Bifidobacterium longum is B. longum subsp. infantis.

### Claim 43 (depends on 41)

The method, or the culture medium, or the composition of claim 41, wherein the Bifidobacterium is B. breve.

### Claim 44

The method, or the culture medium, or the composition of any one of the preceding claims, wherein the commensal bacteria are Lactobacillus and the Lactobacillus may be L. rhamnosus, L. reuteri, or L. plantarum.

### Claim 45 (depends on 44)

The method, or the culture medium, or the composition of claim 44, wherein the Lactobacillus is L. plantarum.

### Claim 46

The method, or the culture medium, or the composition of any one of the preceding claims, wherein the commensal bacteria are Pediococcus and the bacterium may be P. acidilactici or P. pentosaceus.
